Amicus Therapeutics Inc. (FOLD) Financials Nov 14, 2014, 4:11 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Amicus Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 64.36M 922,000 21.43M 18.41M 363,000
Cost of Goods Sold (COGS) incl. D&A 2.13M 2.06M 1.59M - -
COGS excluding D&A 0 0 0 - -
Depreciation & Amortization Expense 2.13M 2.06M 1.59M 1.71M 1.72M
Depreciation 2.13M 2.06M 1.59M 1.71M 1.72M
Amortization of Intangibles - 0 0 0 0
Gross Income 62.23M (1.14M) 19.85M - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 68.05M 54.7M 70.74M 69.04M 60.34M
Research & Development 48.08M 39.04M 50.86M 50.27M 41.94M
Other SG&A 19.97M 15.66M 19.88M 18.76M 18.39M
Other Operating Expense 0 0 0 0 0
Unusual Expense 1.52M 1.41M (2.76M) (53,000) 1.58M
EBIT after Unusual Expense (1.52M) (1.41M) 2.76M 53,000 (1.58M)
Non Operating Income/Expense 64,000 1.28M 70,000 21,000 0
Non-Operating Interest Income 997,000 156,000 160,000 316,000 174,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 278,000 260,000 148,000 89,000 46,000
Gross Interest Expense 278,000 260,000 148,000 89,000 46,000
Interest Capitalized - 0 0 0 0
Pretax Income (6.57M) (56.08M) (48.04M) (52.03M) (63.15M)
Income Tax 0 (1.14M) (3.63M) (3.25M) (3.51M)
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 1.14M 3.63M - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Minority Interest Expense 0 0 0 0 0
Net Income (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
EPS (Basic) (0.29) (1.98) (1.28) (1.07) (1.16)
Basic Shares Outstanding 22.62M 27.73M 34.57M 45.57M 51.29M
EPS (Diluted) (0.29) (1.98) (1.28) (1.07) (1.16)
Diluted Shares Outstanding 22.62M 27.73M 34.57M 45.57M 51.29M
EBITDA (3.7M) (53.78M) (49.3M) (50.63M) (59.97M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Amicus Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 64.36M 922,000 21.43M 18.41M 363,000
Cost of Goods Sold (COGS) incl. D&A 2.13M 2.06M 1.59M - -
COGS excluding D&A 0 0 0 - -
Depreciation & Amortization Expense 2.13M 2.06M 1.59M 1.71M 1.72M
Depreciation 2.13M 2.06M 1.59M 1.71M 1.72M
Amortization of Intangibles - 0 0 0 0
Gross Income 62.23M (1.14M) 19.85M - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 68.05M 54.7M 70.74M 69.04M 60.34M
Research & Development 48.08M 39.04M 50.86M 50.27M 41.94M
Other SG&A 19.97M 15.66M 19.88M 18.76M 18.39M
Other Operating Expense 0 0 0 0 0
Unusual Expense 1.52M 1.41M (2.76M) (53,000) 1.58M
EBIT after Unusual Expense (1.52M) (1.41M) 2.76M 53,000 (1.58M)
Non Operating Income/Expense 64,000 1.28M 70,000 21,000 0
Non-Operating Interest Income 997,000 156,000 160,000 316,000 174,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 278,000 260,000 148,000 89,000 46,000
Gross Interest Expense 278,000 260,000 148,000 89,000 46,000
Interest Capitalized - 0 0 0 0
Pretax Income (6.57M) (56.08M) (48.04M) (52.03M) (63.15M)
Income Tax 0 (1.14M) (3.63M) (3.25M) (3.51M)
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 1.14M 3.63M - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Minority Interest Expense 0 0 0 0 0
Net Income (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (6.57M) (54.94M) (44.41M) (48.79M) (59.63M)
EPS (Basic) (0.29) (1.98) (1.28) (1.07) (1.16)
Basic Shares Outstanding 22.62M 27.73M 34.57M 45.57M 51.29M
EPS (Diluted) (0.29) (1.98) (1.28) (1.07) (1.16)
Diluted Shares Outstanding 22.62M 27.73M 34.57M 45.57M 51.29M
EBITDA (3.7M) (53.78M) (49.3M) (50.63M) (59.97M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
